PMID- 32332068
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20221207
IS  - 2052-4897 (Electronic)
IS  - 2052-4897 (Linking)
VI  - 8
IP  - 1
DP  - 2020 Apr
TI  - Lactobacillus salivarius AP-32 and Lactobacillus reuteri GL-104 decrease glycemic 
      levels and attenuate diabetes-mediated liver and kidney injury in db/db mice.
LID - 10.1136/bmjdrc-2019-001028 [doi]
LID - e001028
AB  - OBJECTIVES: Patients with type 2 diabetes mellitus (T2DM) exhibit strong insulin 
      resistance or abnormal insulin production. Probiotics, which are beneficial live 
      micro-organisms residing naturally in the intestinal tract, play indispensable 
      roles in the regulation of host metabolism. However, the detailed mechanisms 
      remain unclear. Here, we evaluate the mechanisms by which probiotic strains 
      mediate glycemic regulation in the host. The findings should enable the 
      development of a safe and natural treatment for patients with T2DM. RESEARCH 
      DESIGNS AND METHODS: Sugar consumption by more than 20 strains of Lactobacillus 
      species was first evaluated. The probiotic strains that exhibited high efficiency 
      of sugar consumption were further coincubated with Caco-2 cells to evaluate the 
      regulation of sugar absorption in gut epithelial cells. Finally, potential 
      probiotic strains were selected and introduced into a T2DM animal model to study 
      their therapeutic efficacy. RESULTS: Among the tested strains, Lactobacillus 
      salivarius AP-32 and L. reuteri GL-104 had higher monosaccharide consumption 
      rates and regulated the expression of monosaccharide transporters. Glucose 
      transporter type-5 and Na(+)-coupled glucose transporter mRNAs were downregulated 
      in Caco-2 cells after AP-32 and GL-104 treatment, resulting in the modulation of 
      intestinal hexose uptake. Animal studies revealed that diabetic mice treated with 
      AP-32, GL-104, or both showed significantly decreased fasting blood glucose 
      levels, improved glucose tolerance and blood lipid profiles, and attenuated 
      diabetes-mediated liver and kidney injury. CONCLUSION: Our data elucidate a novel 
      role for probiotics in glycemic regulation in the host. L. salivarius AP-32 and 
      L. reuteri GL-104 directly reduce monosaccharide transporter expression in gut 
      cells and have potential as therapeutic probiotics for patients with T2DM.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hsieh, Pei-Shan
AU  - Hsieh PS
AD  - Research and Development Department, Glac Biotech Co., Ltd, Tainan, Taiwan.
FAU - Ho, Hsieh-Hsun
AU  - Ho HH
AD  - Research and Development Department, Glac Biotech Co., Ltd, Tainan, Taiwan.
FAU - Hsieh, Shih-Hung
AU  - Hsieh SH
AD  - Research and Development Department, Glac Biotech Co., Ltd, Tainan, Taiwan.
FAU - Kuo, Yi-Wei
AU  - Kuo YW
AD  - Research and Development Department, Glac Biotech Co., Ltd, Tainan, Taiwan.
FAU - Tseng, Hsiu-Ying
AU  - Tseng HY
AD  - Department of Pediatrics, National Cheng Kung University Hospital, Tainan, 
      Taiwan.
FAU - Kao, Hui-Fang
AU  - Kao HF
AD  - Department of Pediatrics, National Cheng Kung University Hospital, Tainan, 
      Taiwan.
FAU - Wang, Jiu-Yao
AU  - Wang JY
AUID- ORCID: 0000-0003-4540-9822
AD  - Department of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan 
      a122@mail.ncku.edu.tw.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ Open Diabetes Res Care
JT  - BMJ open diabetes research & care
JID - 101641391
SB  - IM
MH  - Animals
MH  - Caco-2 Cells
MH  - *Diabetes Mellitus, Experimental
MH  - *Diabetes Mellitus, Type 2/therapy
MH  - Humans
MH  - Kidney
MH  - *Limosilactobacillus reuteri
MH  - *Ligilactobacillus salivarius
MH  - Liver
MH  - Mice
PMC - PMC7202753
OTO - NOTNLM
OT  - hexokinase
OT  - microbiology
OT  - nutrient regulation
OT  - type 2 diabetes
COIS- Competing interests: P-SH, H-HH, S-HH and Y-WK are employers of Glac Biotech Co, 
      Ltd, Tainan City, Taiwan.
EDAT- 2020/04/26 06:00
MHDA- 2021/06/22 06:00
PMCR- 2020/04/23
CRDT- 2020/04/26 06:00
PHST- 2019/11/12 00:00 [received]
PHST- 2020/02/27 00:00 [revised]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/04/26 06:00 [entrez]
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/04/23 00:00 [pmc-release]
AID - 8/1/e001028 [pii]
AID - bmjdrc-2019-001028 [pii]
AID - 10.1136/bmjdrc-2019-001028 [doi]
PST - ppublish
SO  - BMJ Open Diabetes Res Care. 2020 Apr;8(1):e001028. doi: 
      10.1136/bmjdrc-2019-001028.